Summarized by Daily Strand AI from peer-reviewed source
Researchers have published results from the largest-ever Phase III trial of a CRISPR-based gene therapy for sickle cell disease. The single-infusion treatment edits a patient's own stem cells to reactivate production of fetal hemoglobin — a form of the oxygen-carrying protein that isn't affected by the sickle cell mutation.
Across 48 clinical sites in 12 countries, 94% of treated patients achieved sustained fetal hemoglobin levels high enough to prevent the painful vaso-occlusive crises that define the disease. The therapeutic effect has persisted for over 18 months in the earliest patients, with no significant safety signals emerging.
The treatment works by using CRISPR-Cas9 to disable the BCL11A gene in blood stem cells. This gene normally switches off fetal hemoglobin production after birth. By silencing it, the therapy essentially flips the switch back on, flooding the bloodstream with healthy hemoglobin that prevents red blood cells from sickling.
Sickle cell disease affects roughly 20 million people worldwide, with the heaviest burden in sub-Saharan Africa and among African diaspora communities. Current treatments manage symptoms — pain medication, blood transfusions, hydroxyurea — but none address the root genetic cause.
A one-time curative treatment fundamentally changes the economics of this disease. The lifetime cost of managing sickle cell can exceed $1.6 million per patient. If this therapy can be manufactured at scale and distributed equitably, it could eliminate one of the most common genetic diseases in human history.
This trial also validates the broader promise of CRISPR as a clinical tool. Every successful gene therapy trial builds the evidence base and regulatory precedent for the hundreds of other CRISPR-based therapies currently in development.
Interested in Gene Therapy?
Newsletter
Never miss a breakthrough.
Join 10,000+ curious minds getting biotech stories distilled into plain language. Free, three times a week.